Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance)-Reference-Cited by-同舟云学术

Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance)

Published:2016-02 Issue:2 Volume:27 Page:339-344
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Yoon H.H.,Foster N.R.,Meyers J.P.,Steen P.D.,Visscher D.W.,Pillai R.,Prow D.M.,Reynolds C.M.,Marchello B.T.,Mowat R.B.,Mattar B.I.,Erlichman C.,Goetz M.P.

Funder

North Central Cancer Treatment Group

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/27/2/339/16699647/mdv543.pdf

Reference26 articles.

1. Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study;Briasoulis;J Clin Oncol,2000

2. Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study;Greco;J Clin Oncol,2002

3. Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study–trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01);Culine;J Clin Oncol,2003